Use the Search Fields to Find Information
Page 77 of 360
Rare but relevant: Cannabis use and myocardial infarction
Abstract Pre-clinical research and case reports have linked cannabis use to myocardial infarction (MI) since the 1970s. The association with MI may be specific to
November 20, 2025
Rare but relevant: Cannabinoid hyperemesis syndrome
Please use this link to access this publication. Abstract Cannabinoid hyperemesis syndrome (CHS) is a (probably) rare syndrome that occurs in frequent and chronic cannabis
February 1, 2026
Randomized, placebo-controlled, 28-day safety and pharmacokinetics evaluation of repeated oral cannabidiol administration in healthy dogs
OBJECTIVE To determine the safety and pharmacokinetics of various doses of plant- derived cannabidiol (CBD) versus placebo following repeated oral administration. ANIMALS 20 healthy adult
October 28, 2021
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Background: Central pain in multiple sclerosis (MS) is common and often refractory to treatment. Methods: We conducted a single-center, 5-week (1-week run-in, 4-week treatment), randomized,
September 19, 2019
Randomized Placebo-Controlled Double-Blind Clinical Trial of Cannabis-Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy: Depression is a major confounding factor
OBJECTIVE To assess the efficacy of Sativex, a cannabis-based medicinal extract, as adjuvant treatment in painful diabetic peripheral neuropathy (DPN). RESEARCH DESIGN AND METHODS In
October 7, 2024
Randomized Laboratory Study of Single-Dose Cannabis, Dronabinol, and Placebo in Patients With Schizophrenia and Cannabis Use Disorder Get access Arrow
Please use this link to access this publication. Abstract Background and Hypothesis Up to 43% of people with schizophrenia have a lifetime cannabis use disorder
September 5, 2024
Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review
Please use this link to access this publication. Abstract Anecdotal references, preclinical, and non-randomized studies support the therapeutic potential of cannabinoids for movement disorders (MD).
March 14, 2024
Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy
Abstract OBJECTIVE To assess the effect of oral cannabidiol (CBD) administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with idiopathic epilepsy.
January 11, 2024
Racial and Ethnic Differences in Cannabis Use Following Legalization in US States With Medical Cannabis Laws
Key Points Question Is the legalization of recreational cannabis in the US associated with changes in cannabis use outcomes and cannabis use disorder across racial and
October 7, 2024
Quarterly trends in past-month cannabis use in the United States, 2015-2019
Please use this link to access this publication. Abstract Background Prevalence of cannabis use has been increasing among select subgroups in the US; however, trend
May 17, 2025
Page 77 of 360